Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157148 | 0.92 | HRH3 (0.53) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL14980787 | 0.88 | KMT2A (0.52) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL2205792 | 0.86 | MAPT (0.52) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL7957691 | 0.83 | KMT2A (0.60) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL7006650 | 0.81 | MAPK1 (0.65) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL2873071 | 0.81 | MAPK1 (0.65) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL27042676 | 0.81 | ABCB1 (0.49) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL1193532 | 0.80 | MAPK1 (0.63) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL5467759 | 0.80 | KMT2A (0.64) | KMT2AMEN1ATMHRH3MAPT | |
| SCHEMBL3321214 | 0.79 | KMT2A (0.56) | KMT2AMEN1ATMHRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | Suvalent Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | claimed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | claimed |
| EP-3941905-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | claimed |
| EP-3833664-B1 | SMAD3 INHIBITORS | MOEXA PHARMACEUTICALS LTD (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260027124-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS | MOEXA PHARMACEUTICALS LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4558503-A1 | SUBSTITUTED IMIDAZO [1, 2-A] PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS | Moexa Pharmaceuticals Limited (HK) | 2025-05-28 | — | — | EP | disclosed |
| US-12090149-B2 | SMAD3 inhibitors | MOEXA PHARMACEUTICALS LIMITED (CN) | 2024-09-17 | — | — | US | disclosed |
| CN-112689634-B | SMAD3 inhibitors | 莫扎制药有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024017144-A1 | SUBSTITUTED IMIDAZO [1, 2-A] PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS | MOEXA PHARMACEUTICALS LIMITED (CN) | 2024-01-25 | — | — | WO | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| WO-2015078417-A1 | PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF IN PREPARATION OF HYPOGLAECEMIC DRUG | 四川好医生药业集团有限公司 | 2015-06-04 | — | — | WO | disclosed |
| WO-2008022467-A1 | 2-SUBSTITUTED AZAIN DOLES AND 2 SUBSTITUTED THIENOPYRROLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008022467-A1 | 2-SUBSTITUTED AZAIN DOLES AND 2 SUBSTITUTED THIENOPYRROLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027124-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS | NOX4, NOX1, CBR1 | KMT2A 3740/4885MEN1 4709/4885ATM 3367/4885 |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | CD4, ICOS, NFATC1 | KMT2A 3779/4885MEN1 4604/4885ATM 2348/4885 |
| US-12090149-B2 | SMAD3 inhibitors | SMAD3, SMAD2, STAT3 | KMT2A 1106/4885MEN1 1059/4885ATM 748/4885 |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | KMT2A 4030/4885MEN1 4768/4885ATM 2031/4885 |
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | SUMO1, SUMO2, SUMO3 | KMT2A 1223/4885MEN1 1693/4885ATM 1561/4885 |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | KMT2A 1223/4885MEN1 1693/4885ATM 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.